Reading Time: 6 minutesMND is a complex disease, and the causes are still not fully understood. Researchers all around the world are working tirelessly on different theories to
Author: Kiran Goyal
I work as a Research Officer within the MND Association to help organise the International Symposium and communicating the latest updates of MND research across our social media platforms. I graduated with a master's degree in Neuroscience from Cardiff University in 2023. I have previously supported the awareness of Fragile X syndrome within the UK.
Reading Time: 5 minutesALS is the most common form of MND and these terms are used interchangeably in this blog. MND is a complex disease, with many potential
Reading Time: 7 minutesOn 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration
Reading Time: 4 minutesIt is well known that more men are diagnosed with MND than women. It is not altogether clear exactly why this is the case and
Reading Time: 6 minutesRecent research, led by Professor Guillaume Hautbergue at the University of Sheffield, has found a potential new method of preventing nerve cell death in the
Reading Time: 4 minutesA recent paper published in Brain Communications has identified several lipid (fat-like) molecules that are elevated in MND, specifically amyotrophic lateral sclerosis (ALS) which is
Reading Time: 4 minutesIn 2021, the MND Association, the My Name’5 Doddie Foundation and medical research charity LifeArc established a joint fund – the Motor Neuron Disease Translational
Reading Time: 7 minutesShyuan’s talk was titled ‘Investigating the role of hypermetabolism in ALS’ (C06 in the abstract book) and discussed the research being carried out by her team to try and understand the mechanisms driving hypermetabolism in ALS and what hypermetabolism means clinically for people living with the disease. This blog details Shyuan’s work and looks closely at her observations on hypermetabolism in relation to ALS.
Reading Time: 5 minutesWhat is a clinical endpoint?
A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.
To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.